Journal article
USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway
Abstract
Drug treatments for hepatocellular carcinoma (HCC) often fail because of multidrug resistance (MDR). The mechanisms of MDR are complex but cancer stem cells (CSCs), which are able to self-renew and differentiate, have recently been shown to be involved. The deubiquitinating enzyme ubiquitin-specific protease 22 (USP22) is a marker for CSCs. This study aimed to elucidate the role of USP22 in MDR of HCC and the underlying mechanisms. Using …
Authors
Ling S; Li J; Shan Q; Dai H; Lu D; Wen X; Song P; Xie H; Zhou L; Liu J
Journal
Molecular Oncology, Vol. 11, No. 6, pp. 682–695
Publisher
Wiley
Publication Date
6 2017
DOI
10.1002/1878-0261.12067
ISSN
1574-7891
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
ATP Binding Cassette Transporter, Subfamily BAdaptor Proteins, Signal TransducingAnalysis of VarianceAnimalsApoptosis Regulatory ProteinsCarcinoma, HepatocellularCell Line, TumorChromonesDisease Models, AnimalDown-RegulationDrug Resistance, MultipleDrug Resistance, NeoplasmEnzyme InhibitorsHumansLiver NeoplasmsMaleMiceMice, NudeMorpholinesMultidrug Resistance-Associated ProteinsSirtuin 1Thiolester HydrolasesUbiquitin ThiolesteraseXenograft Model Antitumor Assays